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Ubiquitylation Unit and §Division of Molecular Microbiology,
College of Life Sciences, University of Dundee, DD1 5EH Dundee,
Scotland, United Kingdom
O-GlcNAc signaling is regulated by an opposing pair of
enzymes: O-GlcNAc transferase installs and O-GlcNAcase
(OGA) removes the modification from proteins. The dynamics
and regulation of this process are only beginning to be under-
stood as the physiological functions of both enzymes are being
probed using genetic and pharmacological approaches. This
minireview charts the discovery and functional and structural
analysis of OGA and summarizes the insights gained from
recent studies using OGA inhibition, gene knock-out, and over-
expression.We identify several areas of “knownunknowns” that
would benefit from future research, such as the enigmatic C-ter-
minal domain of OGA.
O-Linked N-acetylglucosamine (O-GlcNAc) is a post-trans-
lational modification of serine and threonine residues on
nuclear, cytoplasmic, andmitochondrial proteins. Since its dis-
covery in the early 1980s (1), O-GlcNAc has been shown to be
involved in the regulation of fundamental cellular processes
in response to nutritional and hormonal cues (2, 3). O-
GlcNAcylation has been implicated in gene regulation (4),
development (5), signal transduction (6, 7), the cell cycle (8),
and proteasomal degradation (9, 10) and shows a degree of
interplay with regulatory protein phosphorylation (11). Dys-
regulation of O-GlcNAc levels is associated with a range of
human diseases, such as cancer (12), diabetes (13), and neuro-
degeneration (14).
Protein O-GlcNAcylation is a dynamic and reversible proc-
ess carried out by two single enzymes: O-GlcNAc transferase
(OGT)2 and O-GlcNAcase (OGA). Here, we review the litera-
ture onOGA, ranging from its discovery 2 decades ago to struc-
tural analysis and genetic/pharmacological approaches toward
probing its function, revealing several gaps in our knowledge of
this key enzyme.
Discovery and Initial Characterization
The O-GlcNAc hydrolase OGA was first purified from rat
spleen by Dong and Hart in 1994 (15), a decade after the dis-
covery of the reversible modification of proteins with O-
GlcNAc. A 1998 study identified it as an antigen expressed by
meningiomas and named the gene MGEA5 (16). The sera of
meningioma patients showed immunoreactivity against two
apparent alternative splicing isoforms, and initial sequence
analyses and biochemical assays suggested hyaluronidase activ-
ity (16). However, in 2001, Gao et al. (17) performed a thorough
biochemical characterization of the recombinantly produced
human enzyme, establishing the neutral pH optimum and
selectivity for GlcNAc over GalNAc that distinguishes OGA
from the lysosomal hexosaminidases HexA and HexB. The
existence of an additional hexosaminidase activity (HexC) in
mammals had been known since the 1970s (18–20) and was
attributed to OGA. Consistent with their subcellular localiza-
tion, the lysosomal hexosaminidases have an acidic pH opti-
mum, and they cleave terminal O-linked -D-N-acetylhexo-
samine residues irrespective of the C4 configuration (GlcNAc
andGalNAc). Their biological role is the degradation of glycans
on proteins and lipids, and their dysfunction is associated with
lysosomal storage disorders, particularly Tay-Sachs and Sand-
hoff diseases (21).Despite their distinct physiological functions,
the existence of these mechanistically related enzymes pertains
toO-GlcNAc research, asmany frequently used small molecule
inhibitors of OGA (most notably PUGNAc) possess little spec-
ificity and simultaneously inhibit the lysosomal hexosamini-
dases. Sequence similarities reveal that OGA belongs to glyco-
side hydrolase family 84 (GH84) in the CAZy Database (22). A
single gene encodes OGA, giving rise to two main isoforms in
vertebrates (23) and a single isoform in lower eukaryotes, e.g.
Drosophila (24) or Caenorhabditis (25). The shorter isoform
lacks the C-terminal domain but retains some OGA activity
(26) and is reported to be localized in the nucleus (27) and in
lipid droplets (28). Full-length OGA is a predominantly cyto-
plasmic and nuclear enzyme (29). In addition to theN-terminal
GH84 domain, OGA was observed to possess another domain
with potential catalytic activity that belongs to the family of
GCN5-related acetyltransferases (Fig. 1) (30). One laboratory
has reported that the OGA C terminus possesses histone
acetyltransferase (HAT) activity in semipure fractions (27, 31).
OGA and HAT activities were speculated to act synergistically,
opening up the chromatin structure (acetylation) and activat-
ing transcription factors through removal of O-GlcNAc (27).
However, later studies (32–34) failed to reproduce these obser-
vations. Although OGA is post-translationally modified (as
reviewed in Ref. 35), the function of these modifications is
largely unknown. Similarly, although O-GlcNAc levels and
OGA/OGT transcription are tightly linked, the mechanisms
underlying this are unexplored.
* This is the second article in the Minireview Series on the Thirtieth Anni-
versary of Research on O-GlcNAcylation of Nuclear and Cytoplasmic
Proteins: Nutrient Regulation of Cellular Metabolism and Physiology by
O-GlcNAcylation.
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O-GlcNAc and OGA have also been described in pro-
karyotes, and GH84 enzymes are encoded in the genomes of
numerous bacterial species. (At the time of writing, there were
185 members of the bacterial branch of GH84 enzymes in the
CAZy Database.) Many of these enzymes contain additional
domains or secretion signals, leaving their physiological func-
tions somewhat in doubt and wholly unstudied. In vitro, how-
ever, several bacterial OGAs have been shown to be highly
effective in removing O-GlcNAc from eukaryotic O-GlcNAc
proteins and have served as models to study the enzymology of
eukaryotic OGAs (36, 37). Intriguingly, a plant ortholog of
OGA has not yet been found, and it is not clear whether
O-GlcNAc in plants is not a dynamic modification or whether
convergent evolution has provided an unrelated enzyme that
functions analogously to OGA (38).
Functional Insights from theO-GlcNAcase Structure
Human OGA (hOGA) is a 103-kDa enzyme comprising an
N-terminal GH84 catalytic domain and a C-terminal HAT-like
domain connected by a 300-amino acid region termed the stalk
domain (Fig. 1). Although hOGA can be expressed and purified
for biochemical studies (29), there is currently no crystal struc-
ture for a eukaryotic OGA; however, valuable insights have
been obtained from structures of apparent bacterial orthologs
(Figs. 1 and 2). The OGA catalytic domain is structurally and
mechanistically related to chitinases, N-acetylhexosamini-
dases, and hyaluronidases in the GH18, GH20, and GH56 fam-
ilies (39). These enzymes perform glycoside hydrolysis with net
retention of the anomeric configuration via a double-displace-
ment reaction with the carbonyl oxygen of the N-acetyl group
acting as a nucleophile, a mechanism described as substrate-
assisted catalysis or neighboring group participation (40, 41).
The active site for the OGA activity of OGA is characterized by
a conserved pair of essential aspartic acid residues, Asp-174 and
Asp-175, in the human enzyme (41), which constitute the cat-
alytic DDmotif. The first insights into the structure of theOGA
catalytic domain came from crystal structures of two bacterial
OGA orthologs in the GH84 family that were reported in 2006,
namelyClostridium perfringensNagJ (CpOGA) (36) and Bacte-
roides thetaiotaomicron hexosaminidase (BtOGA) (37) (Fig. 1).
The catalytic domain consists of a (/)8 or TIM (triose-phos-
phate isomerase) barrel, with the active site located on the
C-terminal face of the barrel, where theGlcNAc sugar occupies
a deep pocket in the surface of the enzyme (Fig. 2). Both struc-
tureswere determined in the presence ofOGA inhibitors, shed-
ding light on the active site architecture, which then facilitated
the targeted generation of catalytically impaired hOGA
through the introduction of point mutations. In addition to the
D174A/D175A doublemutant, which results in loss of catalytic
activity, substitution of either aspartic acid with asparagine
slows down the reaction and has been employed to trap
Michaelis complexes in crystallographic studies (42). The
mutation D285A leads to impaired substrate binding. Detailed
knowledge of the active site architecture was also exploited for
rational design of improved OGA inhibitors, as discussed
below. Subsequent work by He et al. (42) made elegant use of
various substrate analogs to give detailed information about the
reaction coordinate of OGA in the form of crystallographic
“snapshots.”
Several studies have attempted to address the substrate rec-
ognition mechanism of OGA, although it is not yet clear how
OGA regulates O-GlcNAc levels on hundreds of diverse cellu-
lar proteins. Interpretation of the available information is fur-
ther hampered by the fact that instead of O-GlcNAc proteins,
most of these studies have relied on the use of glycopeptides or
colorigenic/fluorigenic pseudosubstrates. One study observing
OGA activity on three differentO-GlcNAc proteins concluded
FIGURE 1. Schematic of thedomain structure of hOGAandapparent bacterial orthologs. TheOGA activity resides in theGHdomain (blue). The position of
the double-aspartate catalytic motif is indicated by the red line. The C-terminal domain harbors the putative HAT domain, which is connected via a helical
bundle referred to as the stalk domain. Flexible/disordered regions are gray: the N-terminal 60 amino acids and the 150-amino acid insertion in the stalk
domain.CpOGA, BtOGA, andOgOGAhave been used to gain insights into the three-dimensional structure of the catalytic domain, whereas putativeOgAT and
SsAT serve as models for the HAT domain. CBM, carbohydrate-binding module; UNK, unknownmodule; FN3, fibronectin-3 homology module.
CpOGA + GlcNAc OgAT + acetyl-coenzyme A 
FIGURE 2. Crystal structures of CpOGA andOgAT serve as models for the
human enzyme. Structures are shown in ribbon representation, with colors
as described for Fig. 1. GlcNAc in the active site of CpOGA and acetyl-CoA in
the active site of OgAT are shown as sticks with black carbons. The internal
surface of the tunnel-like structure inOgAT (gray surface) may form the bind-
ing site for an as yet unidentified ligand.
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that the substrate recognition by hOGA occurs in a conserved
binding groove and involves the interaction of the enzyme’s
surface with O-GlcNAc proteins (43). This is in apparent con-
trast to other work showing that -methyl-GlcNAc, as the
“minimal substrate,” was processed more rapidly than a small
panel of glycoproteins (44), which led the authors to conclude
that any interactions of the protein or peptide with the enzyme
are counterproductive. Amolecular viewof the binding of short
O-GlcNAc peptides in the active site of a catalytically impaired
CpOGA mutant, obtained through crystallographic studies,
showed that interactions were limited to the sequence-inde-
pendent stacking of the peptide backbone to a surface-exposed,
conserved, aromatic residue in OGA (45). Conversely, a com-
bination of molecular docking and molecular dynamics simu-
lation suggests that although sequence-independent interac-
tionswith the peptide component do contribute, the affinity for
OGA substrates varies as a function of the peptide sequence
(46). It should be noted that peptide sequence and length may
have entropic in addition to enthalpic effects on binding and
that their precise conformations in the active sitemay affect not
only binding but also turnover. It is conceivable that substrate
recognition does not proceed along the same lines for the entire
pool of OGA substrates.
Given that sequence conservation in the bacterial homologs
CpOGA and BtOGA is limited to the immediate surroundings
of the active site, these were initially thought to providemodels
for the glycoside hydrolase domain of OGA only. The structure
of a third bacterial OGA fromOceanicola granulosus (OgOGA)
was reported in 2010 (43). OgOGA shows moderate sequence
conservation beyond the catalytic domain, which led to the
understanding that the region connecting the N- and C-termi-
nal domains of eukaryotic OGAs comprises a 200-amino acid
helical bundle termed the stalk domain and a 150-amino acid
unstructured region (Fig. 1). This region harbors Ser-405, the
O-GlcNAc site on hOGA, which itself is a substrate for OGT
(47), as well as residues 404–548, which have been reported to
be required for interaction with OGT (48).
The C-terminal domain of OGA is believed to adopt a GCN5
acetyltransferase-like fold (30). Toleman et al. (27, 31) reported
that semipure fractions of the OGA C terminus showed HAT
activity, which has resulted in the domain being referred to as
the “putative HAT domain” in the literature, although later
studies failed to reproduce these observations. A recent study
could not detect binding of acetyl-CoA to the isolated hOGA
HAT domain recombinantly expressed in Escherichia coli (33).
The crystal structure of a protein from the bacteriumO. granu-
losus that shows significant sequence identity to the hOGA
HAT domain reveals that this domain is likely to be a pseudo-
HAT, as its catalytic core appears to lack the key amino acids
involved in binding of acetyl-CoA and acetyl transfer onto an
acceptor substrate (Fig. 2) (33, 34). Unlike the human protein,
O. granulosus acetyltransferase (OgAT) (33) and a similar pro-
tein from Streptomyces sviceus (SsAT) (34) readily interact with
acetyl-CoA,which is located in a deep substrate-binding pocket
in theOgAT structure (Figs. 1 and 2). Perhapsmost intriguing is
the presence of a large tunnel inOgAT, conserved in the hOGA
HAT domain (as assessed by sequence alignments), which is
presumed to be the binding site for an as yet unidentified
ligand/acceptor (Fig. 2).
O-GlcNAcase Inhibitors as Tools to StudyO-GlcNAc
Signaling
The elucidation of the OGA catalytic mechanism has
enabled the development of potent and selective inhibitors that
have subsequently been used to studyO-GlcNAcylation in cells
and organisms. The available inhibitors have been the subject of
multiple recent reviews (35, 49–51). Ostrowski and van Aalten
(51) focused on their use as probes to studyO-GlcNAc signaling
and covered significant problems with some of the early OGA
inhibitors, PUGNAc and streptozotocin, which are unsuitable
for cell biological studies due to their off-target effects (35).
Here, we will give a brief overview of the two main classes of
mechanism-inspired, potent, and selective OGA inhibitors.
The catalytic mechanism ofO-GlcNAc hydrolysis proceeds via
an oxazoline reaction intermediate. Stable mimics of reaction
intermediates can act as selective enzyme inhibitors, and con-
sequently, thiazoline derivatives of GlcNAc have been explored
asOGA inhibitors (Fig. 3).Modifications of the 1,2-dideoxy-2-
methyl--D-glucopyranoso[2,1-d]-2-thiazoline (NAG-thi-
azoline) acyl side chain (39, 52–54) led to improved selectivity
over GH18, GH20, and GH56 enzymes that employ the same
reaction mechanism. NAG-thiazolines are water-soluble and
synthetically accessible OGA inhibitors with potencies in the
nanomolar-to-micromolar range, with Thiamet-G being the
most selective representative. This family of OGA inhibitors
has been described to possess cardioprotective effects: NAG-
thiazolines protect against ischemia/reperfusion injury, im-
proving contractile function through preservation of the stri-
ated muscle structure (55), and Thiamet-G counteracts TNF-
-induced vascular dysfunction (56). Thiamet-G has also been
proposed as a potential therapeutic for Alzheimer disease, as
discussed in detail in an accompanying minireview (83).
Alzheimer disease and other tauopathies are associated with
phosphorylation-dependent oligomerization of tau protein,
resulting in neurofibrillary tangles. O-GlcNAcylation has been
suggested to negatively regulate tau phosphorylation in a site-
specific manner (57, 58). Oral administration of Thiamet-G in
mice causes an increase in tau S400 O-GlcNAcylation and a
reduction in neurofibrillary tangles in the brainstem, hypothal-
amus, and cortex (59). Transgenic mice overexpressing a
human tau mutant (JNPL3(P301L)) subjected to long-term
OOH
OH
N S
NH
OH
Thiamet-G
OH
O
NH
OH
OH
N
N
GlcNAcstatin G Thiamet-G 
FIGURE 3. The chemical structures of OGA inhibitors are shown in a. Thia-
met-G is a representative of the thiazoline compounds,which are stablemim-
ics of the reaction intermediate. GlcNAcstatin G is themost selectivemember
of the GlcNAcstatin family of inhibitors. In both compounds, selectivity has
been engineeredby elongating theC2 substituent to exploit the depthof the
substrate-binding pocket visible in b, which shows a cross-section of the
active site. GlcNAc is shown in stick representation; the enzyme surface is
shown in blue.
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administration of Thiamet-G display an increase inmotor neu-
rons and body weight paired with a decreased neurogenic atro-
phy of skeletal muscle (60). Similarly, in a recent study in
rTg(tauP301L)4510 mice, Thiamet-G administration caused a
remarkable reduction in pathological 64-kDa tau in brain
homogenates (61).
The GlcNAcstatin family of inhibitors also owes its design to
the elucidation of the catalytic mechanism; these compounds
are designed to mimic the transition state (Fig. 3). The most
potentGH84 inhibitor designed to date is GlcNAcstatin B, with
aKi of 4.6 pM reported for the bacterial enzymeCpOGAand 0.4
nM for hOGA (62). Selectivity forOGAover themechanistically
related lysosomal hexosaminidases was achieved by extending
the N-acyl substituent, capitalizing on the presence of a deep
pocket in the enzyme’s active site that permits OGA to recog-
nize analogs of O-GlcNAc (Fig. 3) (63). GlcNAcstatins (the
most selective compound being GlcNAcstatin G) are potent
cell-permeable inhibitors of hOGA (62, 65) and have been
reported to increase in vivo O-GlcNAc levels in several
human cell lines. GlcNAcstatin G treatment of human
embryonic kidney 293 cells overexpressing he IL-1 receptor
contributed to the discovery of the role of O-GlcNAcylation
in activating the TAK1 (TGF--activated kinase 1) cascade
(66).O-GlcNAcylation of the TAK1 accessory protein TAB1,
induced by IL-1 or osmotic stress, regulates TAK1 signaling,
as O-GlcNAcylated Ser-395 on TAB1 is required for full
TAK1 activation (66). The use of GlcNAcstatin C (62) to
study differentiation of mouse embryonic stem cells revealed
that elevated O-GlcNAc levels lead to delayed embryonic
stem differentiation (67).
Genetic Approaches toward ProbingO-GlcNAcase
Function
A range of mammalian cell lines have been used to study the
possible roles of OGA (68). Contrary to earlier reports, enhanced
OGA expression combined with insulin stimulation in 3T3-L1
cells has suggested that a decrease in cellularO-GlcNAc does not
prevent the onset of insulin resistance (69), also corroboratedwith
studies using selective OGA inhibitors (70, 71). OGA overexpres-
sion inducesmitotic exit in several cell lines, accompanied bywith
a delay in mitotic phosphorylation, an altered cyclin expression
profile, and a disruption in nuclear organization (72). An involve-
ment of OGA in neuronal development has also been reported in
several cell biological studies.OGAoverexpression inculturedpri-
mary chicken forebrainneurons led to an increase in axonbranch-
ing (39). Furthermore, OGA transfection prompted neurons to
enter neurodevelopmental stage III with an axonwithmore filop-
odia (73).
A recent study using orexin neurons (which have a role in
circadian rhythm and feeding behavior) has suggested an
intriguing link between epigenetics, OGA, and neural differen-
tiation (74). This study showed that OGA and HATs (such as
p300 and CBP (cAMP-responsive element-binding protein-
binding protein)) are recruited to the transcription initiation
site of Hcrt, correlating with increased expression of Hcrt and
H3/H4 hyperacetylation.
A null allele of the gene oga-1 in Caenorhabditis elegans
(ok1207) results in viable and fertile worms, alongwith an accu-
mulation of O-GlcNAcylated proteins. However, metabolic
changes lead to alterations in the insulin-like signaling pathway
that controls nutrient storage, life span, and dauer formation
(25). Higher levels ofO-GlcNAcwere observed on nuclear pore
proteins in oga-1(ok1207) animals, and Ser/Thr phosphoryla-
tion profiles appeared to be altered. The insulin pathway is
linked to life span and stress response, and down-regulation of
insulin signaling promotes entry into the dauer stage (75). Con-
sistent with the previous work, Rahman et al. (76) discovered
that oga-1(ok1207) increased the life span of worms by activa-
tion of DAF-16, a transcription factor downstream of insulin
signaling that induces dauer formation. Finally, the oga-1
mutant has been proposed as a tool to study neurodegenerative
diseases (77, 78). Loss of function ofOGAmagnifies the severity
of neurodegenerative proteotoxicity models in C. elegans
(MAPT (microtubule-associated protein tau), -amyloid pep-
tide, and polyglutamine mutant driven to neurons and muscle)
(77). The absence of OGA limits autophagosome formation,
enhancing the proteotoxicity by the accumulation of toxic pro-
tein aggregates (78).
A P-element insertion OGAmutant conferring temperature
resistance has been reported inDrosophila (79). Tissue-specific
knockdown of oga in insulin-producing cells or fat bodies
resulted in an increase in the production ofDrosophila insulin-
like peptides and an increase in carbohydrate levels in hemo-
lymph, mirroring the insulin resistance phenotype in the
C. elegans ogamutant (24).
Overexpression of hOGA in zebrafish embryos leads to
shortened body axes and reduced brain size, with higher rates of
cell death at early developmental stages (80). Epiboly, a key
gastrulation movement that plays a significant role in zebrafish
morphogenesis (81), is delayed, causing a severe disorganiza-
tion of the microtubular and actin cytoskeleton (80), proposed
to be mediated byO-GlcNAc modification of the transcription
factor Pou5f1/Oct4 (80).
The first oga knock-out mouse model has been recently
reported (82). The OGA-deficient mice were generated with a
gene-trapped embryonic cell line by inserting the gene trap vector
in the first intron of oga (64). oga disruption leads to neonatal
lethality associated with a developmental delay, as well as an
increase in O-GlcNAc levels in embryos (82). Homozygous
oga/ embryos showed a reduction in size and weight, with no
visible anatomical abnormalities.At thephysiological level, studies
of proliferation in oga/ mouse embryonic fibroblasts showed
mitotic defects and binucleation, suggesting that cell cycle pro-
gression requires a precise control of O-GlcNAcylation (82).
Mitotic regulators such as aurora kinase B, cyclin B1, andCdc2 are
down-regulated in oga/mouse embryonic fibroblasts (82). It is
clear that the results obtained with genetic and pharmacological
approaches are not always congruent; this suggests that there are
other (noncatalytic) functions of the OGA protein and/or off-tar-
get effects of the currently available inhibitors.
Future Challenges
Although research in the past 2 decades has begun to
uncover some of the roles of OGA, suggesting that it is not a
promiscuous hexosaminidase but an equal partner of OGT in
modulation of theO-GlcNAc proteome,many important ques-
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tions remain unanswered. A single pair of opposing enzymes
orchestrates all intracellular O-GlcNAc, and 1000 proteins
have been reported to be O-GlcNAc-modified to date. Given
the site-specific nature ofO-GlcNAc and the absence of a strict
consensus sequence, the substrate recognition mechanism of
the transferase performs a formidable selection procedure.
Although it is not clear whether all O-GlcNAc proteins are
equally subject to deglycosylation by OGA, inhibition of OGA
in cells typically leads to a global increase in all detectable
O-GlcNAc proteins, which is consistent with the interpretation
that most O-GlcNAc sites on cellular proteins are dynamic
and that OGA activity is essential for maintaining normal
O-GlcNAc levels. Although several studies have addressed
OGA substrate recognition, there is no clarity regarding the
involvement of the protein part of the substrate. There are no
crystal structures of eukaryoticOGAs, let alone complexeswith
fullO-GlcNAcproteins, and thesewill need to be determined to
reveal the principles of (differential) substrate recognition.
Although OGA possesses a HAT-like domain, its function is
unclear. The OGA isoform that lacks the HAT domain retains
some OGA activity, and current data suggest that the hOGA
HAT-like domain is not capable of binding an acetyl donor and
thus not capable of acetyl transfer. Structural work suggests,
however, the presence of an enigmatic tunnel where, in active
acetyltransferases, the acceptor substrate normally binds; the
potential binding partner for this tunnel remains to be identi-
fied. Although there is circumstantial evidence for a role of
O-GlcNAc and OGA in epigenetics, the possible role of the
HAT-like domain will need to be explored.
Although several studies have recently attempted to define
the role of OGA by genetic approaches, they have all relied on a
total disruption of the gene: abrogating OGA activity but also
removing the protein from any complexes of which it might be
a component. With the advent of OGA structural data and
detailed mechanistic insights, it is now possible to design
mutants of the enzyme that are correctly folded yet lack (or are
reduced in) catalytic activity. It will be imperative to exploit
suchmutants in animalmodels to dissect the catalytic and non-
catalytic roles of OGA. We hope that these studies will lead to
unification of pharmacological and genetic approaches toward
the effects of reducing OGA activity in cell lines and disease
models.
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